ジピリダモール
Dipyridamole
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
基本情報
- CAS
58-32-2- 標準SMILES
OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1- InChIKey
IZEKFCXSFNUWAM-UHFFFAOYSA-N- 分子式
- C24H40N8O4
- 平均分子量
- 504.6 g/mol
- 単同位体質量
- 504.31725176
概要
Dipyridamole is a pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots. It has a role as a vasodilator agent, a platelet aggregation inhibitor, an adenosine phosphodiesterase inhibitor and an EC 3.5.4.4 (adenosine deaminase) inhibitor. It is a member of piperidines, a tetrol, a pyrimidopyrimidine and a tertiary amino compound.
名称と識別子
- 優先名称
- Dipyridamole
- IUPAC
- 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol
- 現地名
- ジピリダモール
- 英語名
- Dipyridamole
- 分子式
- C24H40N8O4
- 分子量
- 504.63
名称と別名
dipyridamole58-32-2PersantinDipyridaminePersantineCurantylDipyudamineDipiridamolCleridium 150DypyridamolIv PersantineDipyridamolum
名称をさらに表示
ジピリダモールペルミルチン2,2',2'',2'''-[(4,8-ジ-1-ピペリジニルピリミド[5,4-d]ピリミジン-2,6-ジイル)ジニトリロ]テトラキスエタノールグリオスチンシフノスコロサンN,N,N',N'-テトラキス(2-ヒドロキシエチル)-4,8-ジピペリジノピリミド[5,4-d]ピリミジン-2,6-ジアミンジピリダミンコリボンピロアンヨウリダモールメトロポリンカルジオフルックスニチリダモールコロキシントーモルペルチスタンカルコラジピリダモールS2,2',2'',2'''-[[4,8-ビス(1-ピペリジニル)ピリミド[5,4-d]ピリミジン-2,6-ジイル]ビスニトリロ]テトラキスエタノールDIPYRIDAMOLdypyridamoleAnginalDipyrdamoleDipyridamole (200 mg)ra8RA 8
物性
構造計算による物性補完中
- XLogP
- 0.7
- 極性表面積
- 145 Ų
- 水素結合供与体数
- 4
- 水素結合受容体数
- 12
- 回転可能結合数
- 12
- 重原子数
- 36
- 形式電荷
- 0
- 複雑度
- 561
実験および物理化学的性質
Drugs
Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals -> Used in Switzerland
Pharmaceuticals
LogP1.5
Solubility
Slightly
9.22e-01 g/L
10.7 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs
Breastfeeding; Lactation; Milk, Human; Phosphodiesterase Inhibitors; Vasodilator Agents; Platelet Aggregation Inhibitors
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Pharmaceuticals
Melting Point163 °C
Physical DescriptionSolid
Collision Cross Section
223.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
227.5 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]
222.83 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Warning
H315 (98.7%): Causes skin irritation [Warning Skin corrosion/irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 75 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
危険有害性情報
Other Safety InformationIMAP assessments - Ethanol, 2,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-: Environment tier I assessment
Hazard Classes and CategoriesSkin Irrit. 2 (98.7%)
毒性情報
Hepatotoxicity
Dipyridamole has been associated with a low rate of serum enzyme elevations during therapy, but in large clinical trials the frequency of liver enzyme abnormalities was similar with dipyridamole therapy as with placebo. Cases of clinically apparent acute liver injury from dipyridamole have not been published although hepatitis is listed as a potential side effect in the product label. The clinical features of the liver injury linked to dipyridamole have not been described.
Adverse EffectsThe most frequently reported adverse effects include:
Toxicity SummarySigns and Symptoms of Overdose
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Dipyridamole
Ambiguous-DILI-concern
化学と産業
薬理情報
ATC Code
B - Blood and blood forming organs
QB - Blood and blood forming organs
Protein Binding99%
Pharmacodynamics
Dipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke prophylaxis.
Mechanism of Action
Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation.
Biological Half-Life40 minutes
Metabolism/Metaboliteshepatic
FDA Pharmacological Classification
64ALC7F90C
DIPYRIDAMOLE
Physiologic Effects [PE] - Decreased Platelet Aggregation
Established Pharmacologic Class [EPC] - Platelet Aggregation Inhibitor
Dipyridamole is a Platelet Aggregation Inhibitor. The physiologic effect of dipyridamole is by means of Decreased Platelet Aggregation.
DIPYRIDAMOLE
MeSH Pharmacological Classification
Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
関連反応
1 件
化合物ノート
読み込み中…